MOLGRASTIM
MOLGRASTIM structure
|
Common Name | MOLGRASTIM | ||
|---|---|---|---|---|
| CAS Number | 99283-10-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
Study on the anti-H1N1 virus effects of quercetin and oseltamivir and their mechanism related to TLR7 pathway.
J. Asian Nat. Prod. Res. 14(9) , 877-85, (2012) The antivirus effect of quercetin and oseltamivir on the Toll-like receptor 7 (TLR7) signaling pathway was observed when dendritic cells and macrophages were infected with H1N1. Leukomonocytes were obtained from umbilical cord blood and harvested after stimul... |
|
|
Preoperative mobilization of bone marrow-derived cells followed by revascularization surgery: early and long-term outcome.
Int. J. Artif. Organs 35(1) , 67-76, (2012) Coronary artery disease (CAD), along with its main complications such as acute myocardial infarction (AMI) and congestive heart failure (CHF), remains a serious worldwide problem and affects many patients despite the improvement of medical treatment. The poss... |
|
|
Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Pflugers Arch. 440(5 Suppl) , R81-2, (2000) Myelokathexis is a very rare form of chronic hereditary neutropenia resulting from impaired neutrophil releasing mechanism in the bone marrow. The recombinant human granulocyte-macrophage (molgramostim) and granulocyte (filgrastim, lenograstim) colony stimula... |
|
|
Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients.
Cytokine 12(10) , 1570-4, (2000) We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 microg/kg (n=9) o... |
|
|
New emerging applications of molgramostim in acute myeloid leukaemia.
Expert Opin. Drug Metab. Toxicol. 4(6) , 795-806, (2008) Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the proliferation and differentiation of hematopoietic progenitor cells in the myeloid lineage, and plays a key role in host defence and the inflammatory process. The main schedules ad... |
|
|
Locally applied molgramostim improves wound healing at colonic anastomoses in rats after ligation of the common bile duct.
Can. J. Surg. 48(3) , 213-8, (2005) Several systemic factors, including jaundice, long-term corticosteroid therapy, diabetes and malnutrition, increase the risk of anastomotic dehiscence. The local application of molgramostim (recombinant human granulocyte-macrophage colony stimulating factor) ... |
|
|
Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
Am. J. Clin. Oncol. 25(6) , 547-51, (2002) A randomized phase III study was conducted to assess the addition of molgramostim (GM-CSF) to the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in terms of response rate, progression-free survival, and survival in women with adva... |
|
|
Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
Cancer Invest. 19(6) , 597-602, (2001) Between March 1992 and November 1994, 91 patients with stage III and IV ovarian carcinoma were enrolled in a randomized comparative study of cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 vs. cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2, each ... |
|
|
Safety and efficacy of molgramostim as an adjunctive therapy in critically ill patients with severe sepsis.
Scand. J. Infect. Dis. 35(3) , 175-9, (2003) The aim of this uncontrolled, prospective, clinical study was to investigate the efficacy and safety of molgramostim administration in patients with severe sepsis. The subjects were 20 critically ill, mechanically ventilated patients with severe sepsis in a u... |
|
|
High pregnancy rates with administration of granulocyte colony-stimulating factor in ART-patients with repetitive implantation failure and lacking killer-cell immunglobulin-like receptors.
Hum. Reprod. 25(8) , 2151-2; author reply 2152, (2010)
|